PIVKA-II Test for Hepatocellular Carcinoma at Dr. Essa Lab

PIVKA-II at Dr. Essa Lab

The PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist-II) test, also widely recognized in clinical oncology as Des-gamma-carboxyprothrombin (DCP), is a highly specialized and advanced serum biomarker test utilized primarily for the early detection, surveillance, and management of hepatocellular carcinoma (HCC)—the most common form of primary liver cancer. Under normal physiological conditions, the liver synthesizes prothrombin, an essential blood-clotting protein. This synthesis requires vitamin K to catalyze the carboxylation of specific glutamic acid residues, converting them into gamma-carboxyglutamic acid. This biochemical modification allows prothrombin to bind calcium and participate effectively in the coagulation cascade. However, in the presence of malignant liver cells or a severe deficiency of vitamin K, this carboxylation process is severely impaired. Consequently, an abnormal, non-functional form of prothrombin is released into the bloodstream. This abnormal protein is PIVKA-II.

At Dr. Essa Lab, we utilize state-of-the-art automated immunoassay technology to measure serum PIVKA-II levels with exceptional precision. The clinical importance of this test lies in its high specificity for liver malignancies. Unlike traditional biomarkers such as Alpha-Fetoprotein (AFP), which can frequently elevate in benign liver conditions like chronic hepatitis, cirrhosis, and liver regeneration, PIVKA-II is highly specific to malignant transformation. This makes it an invaluable diagnostic tool for distinguishing benign liver nodules from malignant hepatocellular carcinoma. When used in combination with AFP and ultrasound imaging, PIVKA-II significantly increases the diagnostic sensitivity for early-stage liver cancer, allowing for timely intervention and improved patient outcomes. The test is highly beneficial for patients with chronic liver diseases, including Hepatitis B, Hepatitis C, and non-alcoholic fatty liver disease (NAFLD), who require routine surveillance for liver cancer.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of accuracy and avoid potential interference with your PIVKA-II test results, patients are advised to follow these preparation guidelines:

• Medication History: Inform your prescribing physician and the laboratory staff if you are taking oral anticoagulants, particularly vitamin K antagonists like Warfarin. These medications deliberately block vitamin K action and will cause a marked, non-cancerous elevation in PIVKA-II levels.
• Vitamin Supplements: Discontinue any vitamin K supplements or multivitamins containing vitamin K for at least 48 to 72 hours before the test, unless specifically instructed otherwise by your physician.
• Fasting Requirements: Routine fasting is not strictly mandatory for the PIVKA-II blood test. However, if you are undergoing a panel of tests that includes lipid profiles or blood glucose, a fasting period of 8 to 12 hours may be required.
• Hydration: Stay well-hydrated by drinking plenty of water before your appointment, as this makes venipuncture easier and more comfortable.

During the Procedure

The PIVKA-II test is a straightforward, minimally invasive laboratory investigation. The procedure is conducted as follows:

• Patient Positioning: You will be asked to sit comfortably in a blood collection chair. The phlebotomist will ask you to extend your arm and rest it on a stable support.
• Sanitization: The phlebotomist will locate a suitable vein, typically in the antecubital fossa (the crook of your elbow), and cleanse the skin thoroughly with an antiseptic swab to prevent any contamination.
• Sample Collection: A sterile, single-use needle will be inserted into the vein to draw a small sample of blood into a vacuum collection tube. You may feel a brief, mild pinch or stinging sensation as the needle enters the skin.
• Post-Collection Care: Once the required volume of blood is collected, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze to stop any bleeding. A small adhesive bandage is then applied.
• Duration and Safety: The entire venipuncture process takes less than five minutes. It is performed under strict aseptic conditions to ensure patient safety and prevent infection. You can resume your normal daily activities immediately after the procedure.

When is a PIVKA-II Performed?

Surveillance of Hepatocellular Carcinoma (HCC) in High-Risk Patients

Physicians routinely request the PIVKA-II test for patients diagnosed with chronic liver diseases, such as liver cirrhosis, chronic Hepatitis B, and chronic Hepatitis C. These conditions cause progressive liver damage and significantly elevate the risk of developing hepatocellular carcinoma. Because early-stage HCC is often asymptomatic, regular surveillance using PIVKA-II helps detect malignant changes at a highly treatable stage, long before physical symptoms manifest.

Monitoring Therapeutic Response in Liver Cancer

For patients undergoing treatment for hepatocellular carcinoma—such as surgical resection, liver transplantation, transarterial chemoembolization (TACE), radiofrequency ablation (RFA), or systemic chemotherapy—the PIVKA-II test is performed to evaluate the efficacy of the therapy. A significant decline in PIVKA-II levels post-treatment indicates a successful therapeutic response, while stable or rising levels suggest residual tumor activity or treatment resistance.

Evaluation of Unexplained Liver Masses

When an imaging study, such as an ultrasound, CT scan, or MRI, reveals an unexplained nodule or mass in the liver, the PIVKA-II test is ordered to assist in differential diagnosis. Because benign liver lesions do not typically produce PIVKA-II, elevated levels of this biomarker strongly point toward a malignant hepatocellular origin, helping clinicians distinguish HCC from benign conditions like hemangiomas or focal nodular hyperplasia.

Assessment of Vitamin K Deficiency and Malabsorption

Since PIVKA-II is produced when vitamin K is absent or inactive, this test is highly sensitive for detecting subclinical vitamin K deficiency. It is performed in patients with severe malabsorption syndromes, such as celiac disease, Crohn’s disease, or chronic biliary obstruction, where fat-soluble vitamins like vitamin K are poorly absorbed. This helps clinicians assess the functional impact of vitamin K depletion on hepatic protein synthesis.

Screening for Anticoagulant Therapy Interference or Toxicity

The PIVKA-II test may be utilized to evaluate patients suspected of accidental ingestion or toxicity of vitamin K antagonists, such as rodenticides, or to assess the physiological impact of long-term Warfarin therapy. By measuring the accumulation of decarboxylated prothrombin, clinicians can gain insight into the degree of vitamin K inhibition within the hepatic tissue.

What Does a PIVKA-II Detect?

The PIVKA-II test is a highly sensitive biochemical indicator that detects several critical physiological and pathological states, including:

• Early-stage hepatocellular carcinoma (HCC) before it becomes visible on standard imaging.
• Advanced, metastatic, or recurrent liver cancer.
• Subclinical and clinical vitamin K deficiency in adults and pediatric patients.
• Impaired gamma-glutamyl carboxylase enzyme activity within hepatocytes.
• The presence of microvascular invasion in patients diagnosed with liver tumors.
• The physiological impact of vitamin K antagonist medications (e.g., Warfarin).
• The recurrence of hepatocellular carcinoma following liver transplantation or surgical resection.
• The therapeutic efficacy of transarterial chemoembolization (TACE) or radiofrequency ablation (RFA).
• Malignant transformation of nodules in patients with long-standing liver cirrhosis.
• Biliary tract obstruction leading to impaired absorption of fat-soluble vitamin K.
• Severe dietary malnutrition affecting hepatic clotting factor synthesis.
• The differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma (which typically does not elevate PIVKA-II).
• The presence of portal vein tumor thrombosis, which is highly correlated with extremely elevated PIVKA-II levels.
• Poor prognostic outcomes in patients diagnosed with primary liver malignancies.
• The functional recovery of liver tissue following successful tumor eradication.
• Subtle hepatic dysfunction related to chronic alcohol-induced liver disease.
• Malignant progression of non-alcoholic steatohepatitis (NASH) to HCC.
• Accidental or intentional poisoning with superwarfarin rodenticides.
• Congenital or acquired defects in the vitamin K epoxide reductase (VKOR) system.
• The need for adjuvant therapy in patients with borderline liver tumor resections.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that timely diagnostic results are crucial for effective clinical decision-making and patient peace of mind. The PIVKA-II test is processed using advanced, fully automated immunoassay platforms that ensure both rapid turnaround times and unmatched accuracy. Typically, PIVKA-II test reports are verified and made available within 24 to 48 hours of sample collection.

Dr. Essa Lab provides multiple convenient ways for patients to access their diagnostic reports. Once your report is ready, you will receive an SMS notification containing a direct link to download your secure PDF report. Patients can also access their results online through the official Dr. Essa Lab web portal by entering their lab ID and password. For those who prefer physical copies, reports can be collected directly from any of our conveniently located diagnostic centers across Karachi and other major cities. Our dedicated customer support team is always available to assist you with any queries regarding your report retrieval.

PIVKA-II Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Serum PIVKA-II Level	< 40 mAU/mL	≥ 40 mAU/mL (Indicates potential HCC, vitamin K deficiency, or anticoagulant use)
Hepatic Carboxylation Status	Fully carboxylated, functional prothrombin	Accumulation of non-carboxylated prothrombin (PIVKA-II) due to malignant cell activity
Vitamin K Physiological Activity	Adequate hepatic vitamin K levels and normal enzyme function	Depleted vitamin K levels or blocked enzyme pathways (Warfarin effect)
Tumor Marker Correlation (with AFP)	Both markers within normal reference ranges	Elevated PIVKA-II with or without elevated AFP, strongly suggesting hepatocellular carcinoma
Post-Treatment Surveillance	Undetectable or baseline levels post-resection/ablation	Persistent elevation or rising levels indicating tumor recurrence or incomplete resection
Portal Vein Invasion Risk	Low risk associated with normal or mildly elevated levels	High risk of microvascular invasion associated with extremely high levels (> 400 mAU/mL)
Biliary and Absorptive Function	Normal absorption of fat-soluble vitamins	Elevated PIVKA-II due to malabsorption or obstructive jaundice affecting vitamin K uptake

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for PIVKA-II?

• Established Diagnostic Excellence: Serving patients since 1987 with a reputation built on trust, accuracy, and clinical integrity.
• Highly Qualified Pathologists: Reports are reviewed and verified by experienced consultant pathologists and clinical biochemists.
• State-of-the-Art Technology: Utilizing fully automated, high-precision immunoassay analyzers for reliable biomarker quantification.
• ISO Certified Standards: Operating under strict international quality control protocols to ensure the highest level of laboratory accuracy.
• Convenient Home Sampling: Offering professional and hygienic home sample collection services across Karachi and other major cities.
• Easy Online Report Access: Secure online portal and SMS delivery for quick and hassle-free retrieval of your test results.
• Comprehensive Diagnostic Menu: Ability to perform combined testing, such as PIVKA-II alongside AFP and liver function tests, for a complete clinical assessment.
• Patient-Focused Care: Providing a comfortable, professional, and compassionate environment at all our diagnostic centers.